Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients

Inclusion Criteria: * Patient between 18 and 60 years old (less than 61 years old) * With newly diagnosed with AML according to WHO classification: * With 20% or more blasts in the bone marrow * Patients with history of tumors other than myeloproliferative disorders or myelodysplastic syndromes, having received chemotherapy and/or radiotherapy without previous history of myelodysplastic syndromes are eligible for the present study * High-risk cytogenetics defined as one the following abnormalities : 5/5q-, 7/7q-, t(6,9), 11q23 abnormality excluding t(9;11), 3q abnormality,complex karyotype (\>3 abnormalites) * Left ventricular ejection fraction (LVEF) \> 50% on echocardiography or multigated acquisition (MUGA) scan or similar radionuclide angiographic scan. * Adequate liver function (all of the following) except if secondary to the leukemia: Total bilirubin below 1.5 x upper limit of normal (ULN), AST and ALT below 2.5 x ULN , gamma-GT below 2.5 x ULN, * Adequate kidney function (all of the following): Serum creatinine below 1.5 x ULN, Creatinine clearance above 50 mL/min (Cockroft and Gault formula) * ECOG performance status \< or = 2. * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. * The patient must give written (personally signed and dated) informed consent before completing any study-related procedure which means assessment or evaluation that would not form part of the normal medical care of the patient. * Affiliated to the French Social Security (Health Insurance). Exclusion Criteria: * Previous allogeneic stem cell transplantation. * Pre-existing aplastic anemia * Presence of favourable cytogenetics with t(8;21), t(15;17), or inv(16) * Previous history of MDS or myeloproliferative neoplasm * Uncontrolled active infection. * History of arrythmia. * Cardiac toxicity induced by another anthracycline administration * Maximum cumulative dose reached for any anthracyclin * Allergy to cytarabine, daunorubicin, fish or egg proteins10. Significant neurologic (grade \> 2) or psychiatric disorder, dementia or seizures. * Clinical symptoms suggesting active central nervous system leukemia. * Degenerative or toxic encephalopathy * Severe complications of leukemia such as:Uncontrolled bleeding, Pneumonia with hypoxia or shock * Prior total body irradiation \> 10 Gy. * Known active HIV, Hepatitis B or C infection * Pregnancy or breastfeeding * Concomitant anti-amarile vaccination (yellow fever) * Concurrent treatment with any other anti-cancer therapy except Hydroxyurea